C.R. Bard’s argument to get out of multidistrict litigation is denied.
An Arizona federal judge has dismissed C.R. Bard Inc.’s request to evade multidistrict litigation, ruling the state law claims are not preempted by federal law. Multidistrict litigation (MDL) is a procedure the federal courts use to handle hundreds or thousands of lawsuits that may be filed in federal courts...
A hospital in Joliet, Illinois is urging its patients implanted with inferior vena cava filters to have the medical devices removed. Peter Kraus, partner with blood clot filters law firm Waters Kraus Paul & Siegel, says the announcement is not surprising given the number of adverse reports about IVC filters received by the U.S. Food and Drug Administration. Patients and their physicians...
Hundreds of IVC filter lawsuits against C.R. Bard Inc. (Bard) have been transferred to a federal multi-district litigation (MDL) judge in Phoenix, Arizona. To date, more than 400 blood clot filter cases have been filed in federal court against the New Jersey-based medical device maker. Bard has marketed and sold its IVC blood clot filters as a way to capture blood clots before they reach the...
Inferior vena caval (IVC) filters are not worth the cost and risk involved to justify their widespread use, concludes a study by Yale researchers published in the March 2016 issue of the Journal of the American College of Cardiology. IVC filters are implanted in the body in an effort to prevent pulmonary embolism, in which blood flow in the arteries is blocked by air or blood clots. The...
A discovery schedule has been proposed in the roughly 100 IVC Filter lawsuits pending in a federal MDL in Arizona before U.S. District Judge David G. Campbell. The medical device lawsuits include claims based on injuries caused by the Bard Recovery, G2, and G2 Express retrievable filters. The discovery schedule would apply to the earliest cases filed in the MDL. Those cases might see a trial...
January 21, 2016 – Patients are now being enrolled in a new study to assess the effectiveness and safety of inferior vena cava (IVC) filters — small medical devices implanted in the body to stop blood clots from reaching the heart or lungs. The five-year-long study will involve 2,100 patients at 60 medical sites around the country. PRESERVE (Predicting the Safety and Effectiveness of...
That’s the first question everyone asks. The truth is it’s impossible to know. But we can tell you this. Waters Kraus Paul & Siegel has what it takes to fight against big corporate interests and win. That’s why we’ve taken more mesothelioma trials to verdict than any other firm. And that’s why we’ve recovered more than $1.3 billion for clients like you. Do you think you have a case? Contact us now to speak with an attorney.
3141 Hood Street, Suite 700
Dallas, Texas 75219
Contact Us 800.226.9880
